Samarth Kulkarni Sells 10,349 Shares of CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 10,349 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $499,442.74. Following the transaction, the chief executive officer owned 245,834 shares in the company, valued at $11,863,948.84. The trade was a 4.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Samarth Kulkarni also recently made the following trade(s):

• On Wednesday, March 11th, Samarth Kulkarni sold 9,798 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.80, for a total value of $517,334.40.
• On Thursday, February 19th, Samarth Kulkarni sold 6,967 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $52.58, for a total value of $366,324.86.
• On Tuesday, January 20th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $51.75, for a total value of $1,552,500.00.
• On Thursday, January 22nd, Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $60.23, for a total value of $3,613,800.00.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $47.69 on Thursday. CRISPR Therapeutics AG has a one year low of $30.04 and a one year high of $78.48. The business has a fifty day moving average of $53.60 and a two-hundred day moving average of $57.17. The company has a market cap of $4.58 billion, a P/E ratio of -7.31 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). CRISPR Therapeutics had a negative return on equity of 26.31% and a negative net margin of 16,569.77%.The company had revenue of $0.86 million for the quarter, compared to analyst estimates of $4.72 million. During the same period last year, the company earned ($1.01) earnings per share. The business’s revenue for the quarter was down 97.8% compared to the same quarter last year. Sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 EPS for the current year.

Institutional Investors Weigh In On CRISPR Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Fund Advisors of America Inc FL acquired a new position in CRISPR Therapeutics in the fourth quarter valued at $398,000. Virtu Financial LLC acquired a new stake in CRISPR Therapeutics in the 4th quarter worth about $862,000. Mcguire Capital Advisors Inc. purchased a new stake in CRISPR Therapeutics in the 4th quarter valued at about $25,000. Axxcess Wealth Management LLC grew its holdings in CRISPR Therapeutics by 6.2% in the 4th quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock valued at $683,000 after buying an additional 764 shares during the period. Finally, Corient Private Wealth LLC increased its stake in shares of CRISPR Therapeutics by 5.7% during the 4th quarter. Corient Private Wealth LLC now owns 8,566 shares of the company’s stock valued at $449,000 after acquiring an additional 460 shares during the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Key CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Piper Sandler reiterated an “overweight” rating and raised its price target to $110, signaling strong upside expectations tied to CRSP’s pipeline and future catalysts. Read More.
• Positive Sentiment: Large institutional interest noted (including a new GSK stake and increases by several asset managers), which supports long-term conviction in CRISPR’s platform and programs. Read More.
• Neutral Sentiment: CRISPR completed a sizeable $600M convertible notes offering (reported in recent coverage) that improves near-term liquidity for R&D and operations but could lead to dilution depending on conversion terms. Investors will weigh cash runway benefits against potential share dilution. Read More.
• Neutral Sentiment: Market/price commentary: several news pieces note CRSP is moving more sharply than the broader market today; that reflects the stock’s higher volatility and mixed short-term drivers rather than a single new development. Read More.
• Negative Sentiment: Clustered insider selling on March 16: CEO Samarth Kulkarni, the general counsel and another named insider all sold shares (transactions disclosed in SEC filings). Multiple insiders selling the same day can be read negatively by traders as distribution or reduced confidence from insiders, putting near-term downward pressure on the stock. Read More.
• Negative Sentiment: Operational/financial headwinds persist: recent quarterly results missed EPS and revenue expectations and revenue declined materially year-over-year, keeping profitability and near-term commercialization risk in focus. Analysts’ ratings remain mixed, so negative news can trigger outsized moves. Read More.

Analyst Ratings Changes

Several analysts have recently issued reports on CRSP shares. Bank of America reduced their price objective on CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Needham & Company LLC lifted their price objective on CRISPR Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, February 13th. TD Cowen boosted their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the company a “hold” rating in a research note on Friday, February 13th. Chardan Capital upped their target price on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the company a “buy” rating in a report on Saturday, February 14th. Finally, Citigroup reaffirmed a “buy” rating on shares of CRISPR Therapeutics in a research note on Monday, February 16th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of “Hold” and a consensus target price of $64.53.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.